Augen, like its competitors Longview and Pinetree Capital, has seen its share price drop during the past few months due to its perceived overweighting in the uranium sector. While Augen still owns shares of uranium companies, such as Energy Fuels, these are but a small part of its total resource portfolio. In fact, its EFR exposure has slowly been reduced.

Thus, Augen seems to be unfairly grouped into the peer group of companies with much greater exposures to the uranium sector.